ALK heads into the week before its July 23 earnings date with one of the sharpest month-long recoveries in the airline sector — yet short interest remains elevated and options traders are growing more bullish than at any point in months.
The price move is the headline. ALK closed at $49.11 on Tuesday, up nearly 9% on the week and 33% over the past month. That recovery has been broad across airlines — AAL gained 11.5% on the week, ALGT added 10.6%, and UAL rose 8.1% — but ALK is keeping pace with the faster movers rather than lagging. The sector bid is real, not just a stock-specific story.
Short interest is elevated but not accelerating, which is the more nuanced read underneath the rally. Bears hold 10.5% of the free float short — a meaningful position — and the week-on-week count ticked up about 2.3%. But the longer arc tells a different story: short shares are down 2.5% over the past month, meaning the position was larger before the rally began. Borrowing costs remain negligible at 0.57%, and availability is comfortable at 274% of outstanding short interest, well above the 52-week low of 165% hit in late May. The lending market is not signalling a squeeze — there are roughly two and a half shares available in the borrow pool for every one currently lent out.
Options positioning has shifted sharply in the bull direction. The put/call ratio has compressed to 0.35, more than a standard deviation below its 20-day average of 0.42, and close to the lowest level of the past year (the 52-week low is 0.26). Six weeks ago the PCR was running near 0.57; the steady rotation into calls has tracked almost perfectly with the price recovery. Traders are not hedging this rally — they are chasing it.
The Street is split in a way that matches the stock's whipsaw year. Goldman Sachs holds a Buy but trimmed its target to $61 in April. BMO Capital initiated with Outperform and subsequently raised to $55. UBS has stayed at Buy through multiple target adjustments, landing at $54. The outlier is Citigroup, where analyst John Godyn flipped to Sell in early May with a $32 target — a move that looks increasingly offside given the stock has since rallied from the low $30s toward $49. The consensus mean target of $57.50 implies roughly 17% further upside from current levels. On valuation, the price-to-book has expanded 0.28x over the past month, and the EV/EBITDA multiple of 6.1x has compressed 0.54x over the same period as EBITDA estimates have moved faster than the stock. The ORTEX short score of 58.2 is modestly bearish-leaning but has been remarkably stable — within a two-point range all month — suggesting no dramatic shift in composite sentiment. The EPS forward momentum factor ranks in the 100th percentile on a 30-day basis, though the 90-day reading sits at just the 4th percentile, a reminder that the recent estimate revision trend is very new.
Institutional flow adds mild conviction to the recovery thesis. BlackRock added roughly 1.2 million shares in its most recent filing, pushing its stake to 10.5% of shares outstanding. American Century and Capital Research also added meaningfully, buying 607,000 and 830,000 shares respectively. The insider picture is less supportive — the CFO and CEO both sold in February near $55-57, well above where the stock trades today, and there have been no purchases on record. The net insider position over 90 days is a modest positive in share count terms due to award grants, but the economic direction of discretionary trading has been to reduce exposure.
Earnings on April 23 produced a 2% gain on the day, only for the stock to give back 4% over the following five days. The two prints before that both saw immediate drops of 1.3% and 6.3%, with five-day moves of -7.3% and -8.6%. The July 23 date arrives into a much stronger tape, but the pattern of post-earnings drift lower is worth noting as the setup builds. Whether the rally's momentum is sufficient to overcome that historical tendency is the question the next six weeks will clarify.
See the live data behind this article on ORTEX.
Open ALK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
